Zeta Global Holdings Corp. (ZETA)
NYSE: ZETA · Real-Time Price · USD
15.08
-0.57 (-3.64%)
At close: Aug 1, 2025, 4:00 PM
15.12
+0.04 (0.27%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Inozyme Pharma Stock Forecast
Stock Price Forecast
The 14 analysts that cover Inozyme Pharma stock have a consensus rating of "Strong Buy" and an average price target of $28.57, which forecasts a 89.46% increase in the stock price over the next year. The lowest target is $15 and the highest is $45.
Price Target: $28.57 (+89.46%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 10, 2025.
Analyst Ratings
The average analyst rating for Inozyme Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 5 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 14 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | +32.63% | Jun 10, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $27 → $16 | Hold | Maintains | $27 → $16 | +6.10% | May 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $30 → $25 | Buy | Maintains | $30 → $25 | +65.78% | May 2, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $28 → $26 | Strong Buy | Maintains | $28 → $26 | +72.41% | May 2, 2025 |
| Needham | Needham | Strong Buy Maintains $43 → $25 | Strong Buy | Maintains | $43 → $25 | +65.78% | May 2, 2025 |
Financial Forecast
Revenue This Year
1.27B
from 1.01B
Increased by 25.88%
Revenue Next Year
1.48B
from 1.27B
Increased by 17.14%
EPS This Year
0.69
from -0.38
EPS Next Year
0.88
from 0.69
Increased by 27.97%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.3B | 1.6B | 1.9B | ||
| Avg | 1.3B | 1.5B | 1.8B | ||
| Low | 1.2B | 1.3B | 1.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 30.0% | 24.2% | 25.3% | ||
| Avg | 25.9% | 17.1% | 18.7% | ||
| Low | 19.9% | 6.2% | 8.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.96 | 1.21 | 1.42 | ||
| Avg | 0.69 | 0.88 | 1.04 | ||
| Low | 0.46 | 0.62 | 0.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 76.3% | 61.7% | ||
| Avg | - | 28.0% | 19.1% | ||
| Low | - | -9.9% | -6.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.